Analyst firms · Leerink Partners · CMPX
Leerink Partners CMPX price target and rating history
Compass Therapeutics Inc. (CMPX) · Health Care
Leerink Partners rates Compass Therapeutics Inc. (CMPX) Outperform with a $6 price target, as of its latest action on Apr 2, 2025. It has published 3 rating actions on CMPX since December 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a CMPX price target in the last 12 months, the median target is $10.
- Current rating
- Outperform
- Price target
- $6
- Median target, all firms
- $10
- Actions on CMPX
- 3
Leerink Partners price target on CMPX
Every Leerink Partners rating on CMPX
- Apr 2, 2025
- Nov 15, 2024
- Dec 20, 2021
How other firms rate CMPX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wedbush | Neutral | $1 | Sep 23, 2026 |
| Ladenburg Thalmann | Buy | $5 | Jul 1, 2026 |
| Raymond James | Mkt Perform | Apr 28, 2026 | |
| Craig-Hallum | Buy | $15 | Feb 13, 2026 |
| William Blair | Outperform | Jan 5, 2026 | |
| Citizens JMP | Mkt Outperform | $10 | Dec 3, 2025 |
| Canaccord Genuity | Buy | $10 | Dec 3, 2025 |
| Cantor Fitzgerald | Overweight | Dec 3, 2025 |
Questions about Leerink Partners and CMPX
- What is Leerink Partners's price target for CMPX?
- Leerink Partners's latest stated price target for Compass Therapeutics Inc. (CMPX) is $6, from its action on Apr 2, 2025.
- What is Leerink Partners's rating on CMPX?
- Leerink Partners rates CMPX Outperform, a bullish rating, as of Apr 2, 2025.
- When did Leerink Partners last change its view on CMPX?
- On Apr 2, 2025, Leerink Partners upgrades to Outperform from Market Perform, price target $6.
- How does Leerink Partners's CMPX target compare with other analysts?
- Across 5 firms with a CMPX price target in the last 12 months, the median target is $10.
More CMPX rating histories
All Leerink Partners ratingsCMPX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.